Publicité
Publicité

ENLV

ENLV logo

Enlivex Therapeutics Ltd. Ordinary Shares

0.92
USD
Sponsorisé
+0.08
+9.56%
09 janv., 13:52 UTC -5
Ouvert

ENLV Rapports sur les bénéfices

Ratio de surprise positive

ENLV a dépassé 17 des 29 dernières estimations.

59%

Prochain rapport

Date du prochain rapport
30 mars 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.11
Variation implicite de Q3 25 (Revenue/ EPS)
--
/
+22.22%
Variation implicite de Q4 24 (Revenue/ EPS)
--
/
-52.17%

Enlivex Therapeutics Ltd. Ordinary Shares earnings per share and revenue

On 14 nov. 2025, ENLV reported earnings of -0.09 USD per share (EPS) for Q3 25, beating the estimate of -0.12 USD, resulting in a 26.47% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.63% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analystes forecast an EPS of -0.11 USD, with revenue projected to reach -- USD, implying an hausse of 22.22% EPS, and hausse of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
26 déc. 2025 Pour Q4 25
Estimation
-$0.49
Actuel
-
Surprise
-
FAQ
For Q3 2025, Enlivex Therapeutics Ltd. Ordinary Shares reported EPS of -$0.09, beating estimates by 26.47%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.63%, changed from $0.99 before the earnings release to $0.98 the day after.
The next earning report is scheduled for 30 mars 2026.
Based on 3 analystes, Enlivex Therapeutics Ltd. Ordinary Shares is expected to report EPS of -$0.11 and revenue of -- for Q4 2025.
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité